This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cramer's 'Mad Money' Recap: Europe's Problems Difficult but Can Be Solved

Stocks in this article: SBUX MCD RL F FB MS CREE FLR NXPI CLNE VVUS CRI SGEN CAT

NXP Semiconductors (NXPI): "This market is too tough. I don't want you to buy any semiconductors right now. See you in September."

Clean Energy Fuels (CLNE): "This is completely speculative. You're betting on companies switching to natural gas. They haven't done it yet, so until then you're stuck."

VIVUS (VVUS): "I like it as a speculation. I think it's a good one."

Carter's (CRI): "Keep looking, don't touch. They have no growth. I don't want to touch any no-growth situations."

Executive Decision

In the "Executive Decision" segment, Cramer sat down with Clay Siegall, president and CEO of Seattle Genetics (SGEN), another cancer-fighting company presenting at the American Society of Clinical Oncology conference this week.

Siegall explained that Seattle Genetics' cancer drugs use target antibodies to dock with tumor cells and kill them while leaving surrounding, healthy cells untouched. He said the result is a less toxic, targeted therapy. Seattle Genetics is currently developing seven such treatments to attack both solid and liquid tumors.

Another part of Seattle Genetics' strategy is to utilize local community doctors, rather than large hospitals, to administer their treatments. He said the 30-minute infusions are easy to administer and patients much prefer to be seen by their regular doctors.

When asked about the potential of their treatments, Siegall said his company has 10 to 15 different trials in the pipeline and he's confident the treatments will be successful in treating different types of cancers as well.

With the frontline treatment for cancer having changed little since its introduction in 1977, Cramer said companies like Seattle Genetics are offering hope for newer, safer and more effective cancer treatments, which is why he remains bullish on the company.

No Huddle Offense

In his "No Huddle Offense" segment, Cramer looked at the shares of Caterpillar (CAT), an industrial stock in the crosshairs of a potential global recession, to ask, "What's a fair valuation for this earth-moving equipment powerhouse?"

Cramer said Caterpillar shares have already fallen 30% from their high of $116. However, during the recession of 2008 and 2009, a time when earnings fell by 60%, shares of Caterpillar fell a whopping 75%. Could investors be in for a similar decline now to $36 a share?

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs